Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Vesalius Therapeutics

- PMLiVE

Sumitomo Pharma’s stem cell therapy for Parkinson’s given limited approval in Japan

The company has been given manufacturing and marketing authorisation for the therapy

- PMLiVE

Annovis partners with NeuroRPM on new AI platform to track Parkinson’s symptoms

The platform will passively collect data to understand treatment responses in everyday life

- PMLiVE

GSK to acquire 35Pharma for $950m including a potential drug for pulmonary hypertension

PH has a five‑year survival rate of only around 50% and affects up to 82 million people worldwide

- PMLiVE

GSK’s Arexvy RSV vaccine receives expanded EC approval for use in adults

RSV affects approximately 64 million people around the world each year

- PMLiVE

GSK’s Nucala approved by MHRA for uncontrolled COPD

Symptoms of COPD include breathlessness, persistent cough and frequent chest infections

- PMLiVE

GSK’s Blenrep approved by FDA for multiple myeloma

Approval supported by positive results from phase 3 trial

- PMLiVE

Mission Therapeutics advances Parkinson’s disease candidate

The company also received a grant from the Michael J. Fox Foundation and Parkinson’s UK

- PMLiVE

PhotoPharmics’ new advisory board to guide launch of FDA Breakthrough device for Parkinson’s

The US-based company develops light-based therapies for neurodegenerative conditions

- PMLiVE

GSK and Hengrui enter multi-programme collaboration agreement worth $12bn

The deal includes a PDE3/4 inhibitor in clinical development for COPD

- PMLiVE

GSK’s Blenrep combinations granted EC approval for relapsed/refractory multiple myeloma

More than 50,000 cases of the blood cancer are diagnosed in Europe each year

- PMLiVE

GSK’s Blenrep combination recommended by NICE to treat multiple myeloma

The decision means that eligible patients in England will be the first in the world to access the combination

- PMLiVE

GSK to acquire Boston’s liver disease candidate efimosfermin in deal worth up to $2bn

Steatotic liver disease affects approximately 5% of the global population

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links